Biotie Therapies Making Strides In Neurodegenerative Diseases

Finnish Biotech company Biotie Therapies BITI BIOZF hopes to raise $56 million in its upcoming IPO this Friday, June 12.

The company will offer 3.8 ADSs at price of $14.82, up 12 percent from its original offer. The deal was initially set for 3.4 million ADSs at the same price.

Biotie will list on the NASDAQ under the ticker BITI. It currently trades on the Finnish stock exchange under the ticker BTHV1 and over the counter under the ticker BIOZF.

Brief History

Biotie acquired Synosia Therapeutics in 2011.

The biotech also developed a product called Selincro to treat alcohol dependence currently commercialized by Lundbeck and remains a source of potential milestone payments and continuing royalties.

Current Undertakings

Tozadenant is taken orally and proven to be safe and well-tolerated in the company’s ten clinical trials.

Biotie has two other product candidates in its pipeline being developed. SYN120 for Parkinson’s disease, dementia and Alzheimer’s disease; and BTT1023 to treat primary sclerosing cholangitis, which is a form of liver disease. Both are still in early Phase 1 and 2 clinical trials.

Sphere Of Influence

The market size for Parkinson therapeutics in the U.S., five major EU markets, Brazil and Japan is approximately $3.6 billion and is projected to grow to $5.3 billion by 2022 with the U.S. estimated to have the largest Parkinson’s therapeutics market share at 44 percent.

Financials

For Q1 ending March 31, Biotie reported $871 thousand in revenue compared with $5.10 million in 2014. Revenue consists of royalty and milestone payments received under its Lundbeck agreement for Selincro and non-refundable milestone payments under its UCB agreement following the completion of Phase 2b and 3 developmental trials.

Revenue decreased to $16.7 million in 2014 from $31.1 million in 2013. The decrease was due to a fall in milestone payments. Revenue from Lundbeck helped offset the decline.

The company’s net loss increased to ($39.5) million at the end of 2014 compared to a loss of ($6.47) in the previous year. This loss was due to the company’s heavy R&D and general and administrative expenses, as it works to commercialize its product pipeline. R&D expenses allocated to tozadenant were $9.86 million in 2014 compared with the overall R&D expense of $19.3 million.

At the end of Q1 in 2015, the company reported $7.09 million in cash on its books. Over the same time period, total assets were $106 million and total liabilities equaled $44.4 million.

Some of Biotie’s current investors and members of its board have expressed indications of interest to purchase up to $25 million of ADSs in the deal.

Conclusion and Pricing Info

Biotie expects net proceeds to be $49.1 million. It intends the use the proceeds along with its cash to fund its Phase 3 double-blind clinical trial on tozadenant in Parkinson’s through completion. The company also intends to fund SYN120 Phase 2a clinical trial in Parkinson’s and dementia, and the BTT1023 Phase 2 clinical in PSC.

The company plans to offer 3.8 million ADSs at a price of $14.82 per ADSs. Biotie will list on the NASDAQ under the ticker BITI and it already trades on the OTC Pink Sheets under BIOZF. Given the midpoint of the range, this microcap stock’s market cap is estimated to be $56 million. The main underwriters for the offering are RBC Capital Markets, Stifel and JMP Securities. Shares are expected to price Thursday night.